Insider Selling: Regina E Groves Unloads $288K Of AtriCure Stock - AtriCure (NASDAQ:ATRC)
AtriCure (NASDAQ:ATRC) Board Member Regina E Groves sold 5,313 shares for $288,070 on September 14, according to an SEC filing. ATRC shares were down 0.97% at $55.79 on Tuesday. The company reported 12.83% revenue growth and a 77.23% gross margin as of June 30, 2026, but has a high P/E ratio of 265.67 and an EPS of 0.18.
How this was made
The 30-second read
Why it matters
The transaction is modest and caused a sub‑1% price dip, suggesting limited market impact.
Market read
A minor insider sell with negligible trading relevance; no actionable signal for traders.
What to watch
Potential upcoming clinical data releases could outweigh the effect of this small insider transaction.
Background
SEC Form 4 filing disclosed a board member's sale of AtriCure shares, a routine insider transaction.
Ticker impact
Board member Regina E Groves sold 5,313 shares of AtriCure for $288,070, and the stock fell 0.97% after the filing.
Limited short-term downside pressure, but no major trend change expected.
The sale size is modest relative to market cap and the price move is under 1%.
Market effects
Minimal impact on the broader health‑care device sector.
No notable regional effect; the filing is U.S.‑focused.
Insignificant for global markets.
Counterpoint
The insider may have personal liquidity needs; the sale does not signal lack of confidence.
Key entities
- personRegina E Groves
Board member of AtriCure who sold shares.
- companyAtriCure Inc.
Medical device company focused on atrial fibrillation treatments.
